Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Pediatric Studies Characteristics - Detail
  • Print
  • Share
  • E-mail
-
 
Approval Date:  10/17/2011
 
Trade Name:  Reyataz
 
Generic or Proper Name (*):  atazanavir
 
Indications Studied:  Treatment of HIV - 1 infection
 
Therapeutic Category:  Antiviral
 
Ages Studied:  91 days - 21 years
 
Study #:  1
 
Study Type:  Safety/Pharmacokinetic
 
Study Design:  Open Label/Traditional Pharmacokinetic
 
No Patients:  105
 
No Centers:  36
 
No Countries:  2
 
BPCA(B), PREA(P):  B, P
 
Unknown:  0
 
Countries:  North America, including Puerto Rico and, South Africa
 
-
-